Literature DB >> 29140756

Cellular and Molecular Mechanisms of Autoimmune Hepatitis.

G J Webb1, G M Hirschfield1, E L Krawitt2,3, M E Gershwin4.   

Abstract

Autoimmune hepatitis is an uncommon idiopathic syndrome of immune-mediated destruction of hepatocytes, typically associated with autoantibodies. The disease etiology is incompletely understood but includes a clear association with human leukocyte antigen (HLA) variants and other non-HLA gene variants, female sex, and the environment. Pathologically, there is a CD4+ T cell-rich lymphocytic inflammatory infiltrate with variable hepatocyte necrosis and subsequent hepatic fibrosis. Attempts to understand pathogenesis are informed by several monogenetic syndromes that may include autoimmune liver injury, by several drug and environmental agents that have been identified as triggers in a minority of cases, by human studies that point toward a central role for CD4+ effector and regulatory T cells, and by animal models of the disease. Nonspecific immunosuppression is the current standard therapy. Further understanding of the disease's cellular and molecular mechanisms may assist in the design of better-targeted therapies, aid the limitation of adverse effects from therapy, and inform individualized risk assessment and prognostication.

Entities:  

Keywords:  T cells; autoantibodies; autoimmune hepatitis; autoimmunity; cirrhosis; hepatocyte

Mesh:

Year:  2018        PMID: 29140756     DOI: 10.1146/annurev-pathol-020117-043534

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  31 in total

Review 1.  Pathogens and autoimmune hepatitis.

Authors:  U Christen; E Hintermann
Journal:  Clin Exp Immunol       Date:  2018-10-07       Impact factor: 4.330

2.  Redox regulation of hepatic NLRP3 inflammasome activation and immune dysregulation in trichloroethene-mediated autoimmunity.

Authors:  Hui Wang; Gangduo Wang; Yuejin Liang; Xiaotang Du; Paul J Boor; Jiaren Sun; M Firoze Khan
Journal:  Free Radic Biol Med       Date:  2019-08-13       Impact factor: 7.376

Review 3.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

Review 4.  [Autoimmune hepatitis-standard and second-line therapy].

Authors:  R Taubert; E Jaeckel
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

Review 5.  The emerging role of ferroptosis in non-cancer liver diseases: hype or increasing hope?

Authors:  Lihong Mao; Tianming Zhao; Yan Song; Lin Lin; Xiaofei Fan; Binxin Cui; Hongjuan Feng; Xiaoyu Wang; Qingxiang Yu; Jie Zhang; Kui Jiang; Bangmao Wang; Chao Sun
Journal:  Cell Death Dis       Date:  2020-07-09       Impact factor: 8.469

Review 6.  Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis.

Authors:  Marco Sciveres; Silvia Nastasio; Giuseppe Maggiore
Journal:  Front Pediatr       Date:  2019-09-20       Impact factor: 3.418

7.  The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice.

Authors:  Han Wang; Xinxia Feng; Ping Han; Yu Lei; Yujia Xia; Dean Tian; Wei Yan
Journal:  Mol Med Rep       Date:  2019-10-16       Impact factor: 2.952

Review 8.  Stem cell therapies for autoimmune hepatitis.

Authors:  Ahmed Lotfy; Aya Elgamal; Anna Burdzinska; Ayman A Swelum; Reham Soliman; Ayman A Hassan; Gamal Shiha
Journal:  Stem Cell Res Ther       Date:  2021-07-07       Impact factor: 6.832

9.  Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis.

Authors:  Richard Taubert; Jana Diestelhorst; Norman Junge; Martha M Kirstein; Sven Pischke; Arndt Vogel; Heike Bantel; Ulrich Baumann; Michael P Manns; Heiner Wedemeyer; Elmar Jaeckel
Journal:  Sci Rep       Date:  2018-11-28       Impact factor: 4.379

10.  Plasma proteomic analysis of autoimmune hepatitis in an improved AIH mouse model.

Authors:  Han Wang; Wei Yan; Zuohua Feng; Yuan Gao; Liu Zhang; Xinxia Feng; Dean Tian
Journal:  J Transl Med       Date:  2020-01-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.